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THE objectives  of  this  work  are  to  investigate  the
incorporation of arachidonic acid (AA) in the human
myeloma cell lines OPM2, U266 and IM9, and to assess
the effect of AA and lipoxygenase products of AA on
their  growth.  The  kinetics  of  acylation  of  [3H]AA
indicates  that  myeloma  cells  incorporate  AA  into
their  membrane  phospholipids  and  triglycerides.
PLA2-treatment and base hydrolysis experiments con-
firm that [3H]AA is incorporated unmodified in U266,
IM9  and OPM2  phospholipids, and is  linked by  an
ester  bond.  Prelabeling-chase experiments  indicate
no  trafficking  of  labeled  AA  among  the  various
phospholipid  species.  Addition  of  AA  and  lipoxy-
genase products of AA (leukotriene B4 and C4, lipoxin
A4 and B4, 12- and 15-hydroxyeicosatetraenoic acid)
have no effect on U266, IM9 and OPM2 proliferation
assessed by [3H]thymidine incorporation into DNA. In
conclusion,  while  human  myeloma  cells  readily
incorporate  AA  in  their  membrane  phospholipids
and triglycerides, AA and lipoxygenase products are
not important modulators of their proliferation.
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Introduction
The lipoxygenase pathway converts arachidonic acid
(AA),  a  20-carbon  polyunsaturated  fatty  acid,  in
hydroxyeicosatetraenoic acid (HETE),  lipoxins  (LX)
and  leukotrienes  (LT).1 Lipoxygenase  inhibitors
enhance the proliferation of human B cells in vitro,2
while they have antiproliferative effects on malignant
hematopoietic cell lines,3,4 thus suggesting a role of
endogenous  lipoxygenase  metabolites of AA during
cell  proliferation.  While  exogenous  lipoxygenase
products  modulate  cell  proliferation  in  several  cell
types,5–7 their effect (if any) on the growth of human
B cell lines are not documented. In this study we have
investigated the incorporation of AA in three human
myeloma cell lines (i.e. IM9, U266 and OPM2) and the
effect of AA and lipoxygenase  metabolites,  such as
LTB4, LTC4, LXA4, LXB4, 12-HETE  and 15-HETE, on
their proliferation.
Materials and Methods
Incorporation of [
3H]AA in myeloma cells
U266,  IM9  and  OPM2  were  obtained  from  the
American Type  Culture  Collection (Rockville,  MD).
Cells  were  grown  in  suspension  in  RPMI  1640
supplemented  with  10%  fetal  calf  serum  (FCS)
(Gibco, Cergy Pontoise, France), penicillin (100U/ml)
and streptomycin (100mg/ml) at 37°C in 5% CO2 in
air.  Before use,  cells were washed twice  in  Hanks’
balanced salts  solution  (HBSS)  and  numerated. The
incorporation of [3H]AA (Amersham, Les Ulis, France)
was performed with cells (33 106) in 1ml of RPMI
1640 medium without FCS. [3H]AA (0.1m Ci; 210Ci/
mmol)  was  added  into  the  medium  for  various
periods of time. At the end of the experiments, cells
were  harvested  by  centrifugation  (8003 g,  10min)
and then stored at –20°C until use. For AA remodeling
studies, cells were labeled with [3H]AA for 30min,
washed with HBSS,  and incubated in  1ml  of  RPMI
1640  without FCS  for 7h or used immediately. For
these experiments cells were stored as above.
Lipid extraction
Cells were mixed with 1ml of 0.1% sodium dodecyl
sulfate in water, and incubated for 30min at 56°C with
3ml  of  chloroform/methanol  (2:1,  v/v). The  chlor-
oformic extract was washed with 5ml of 0.1M KCl/
methanol/chloroform (96:92:6, v/v/v), and was evap-
orated.8 The dry extract was recovered in 150m l of
chloroform and applied to a thin-layer chromatography
(TLC)  plate  (Silica  gel  60  (203 20cm,  0.25mm),
Merck) and submitted to  TLC.  The plate was developed
in  the  mixture  of  diethyl  ether/hexane/acetic  acid
(70:30:1, v/v/v).9 Each lane was divided into areas of
0.5cm in length which were scraped into vials, and
radioactivity  was  measured  on  a  Packard  liquid
scintillation  counter.  Solutions  of  monoglycerides
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lipids  (PL)  and AA  (Sigma,  Saint  Quentin  Fallavier,
France) were used as standards and visualized with
iodine vapor.
Analysis of labeled PL
For the separation of the various species of cellular
PL, the corresponding areas were scraped from the
TLC  plates  and  were  extracted  with  chloroform/
methanol (2:1, v/v). Samples were then rechromato-
graphed  using  a  solvent  system  of  chloroform/
methanol/acetic  acid/water  (50:30:8:4,  v/v/v/v).8
Each lane was divided into areas of 0.5cm in length
and processed as above. Solutions of phosphatidyle-
thanolamine  (PE),  phosphatidylcholine  (PC),  phos-
phatidylserine  (PS)  and  phosphatidylinositol  (PI)
(Sigma)  were used as standards and visualized with
iodine  vapor.  In  this  chromatography,  PI  and  PS
migrated to the same area.
Base hydrolysis and PLA2 treatment of labeled
PL
In  a  first  set  of  experiments,  the  labeled  PL  were
resuspended  in  1ml  of  2M  KOH  in  ethanol/water
(3:1,  v/v)  as  previously  reported.9 After  40min  at
60°C, 1ml of water and 1ml of 6N HCl were added to
the  mixture  to  acidify  the  phase  (pH  3).  Labeled
compounds were extracted with chloroform/metha-
nol (2:1, v/v) and rechromatographed using a solvent
system of diethyl ether/hexane/acetic acid (70:30:1,
v/v/v). The amount of radioactivity migrating with PL
and  free AA  was  determined  by  liquid  scintillation
counting. In another set of experiments, labeled PL
were  hydrolysed  with  PLA2 from  bovine  pancreas
(Sigma).  Briefly,  labeled  PL  samples  were  resus-
pended in 1ml of diethyl ether/methanol (95:5, v/v)
containing  50m l  of  Tris  buffer  (0.05M),  CaCl2
(25mM), EDTA (1mM), and 1mg of phospholipase.
The reaction mixture was incubated at 37°C for 2h
with continuous shaking. After evaporation of solvent,
samples  were  rechromatographed  as  for  base
hydrolysis.
Proliferation studies
U266,  IM9  and OPM2 cells (53 105 per well)  were
cultured in 96-well microtiter plates in 100m l of RPMI
1640 with 10% FCS in the presence of AA, LTB4, LTC4,
LXA4,  LXB4,  12-HETE  and  15-HETE  (1m M)  or  the
appropriate  vehicle  (10m l  of  2%  human  serum
albumin).10 After  64h  of  incubation,  cultures  were
pulsed  for  8h  with  1m Ci/ml  of  [3H]thymidine  and
cells were harvested using a Skatron cell harvester.
Each experiment was carried out  on n=6  samples.
Data  were  compared  by  Mann–Whitney  U-test.  A
P<0.05 was considered significant.
Results and Discussion
As reported in Fig. 1, OPM2, U266 and IM9 incorpo-
rate [3H]AA into their membrane lipids. The distribu-
tion  of  label  in  cell  lipids  as  a  function  of  time
indicates that the majority of label is found with TG
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FIG. 1. Time-course of [
3H]AA incorporation into U266 (A),
OPM2  (B)  and  IM9  (C)  cell  lipids.  Cells  (3  3 10
6)  were
incubated with [
3H]AA for 10, 60 and 300min. Cell lipids were
extracted  and  separated  as  described  in  Materials  and
Methods. Results are expressed as the percentage of total
radioactivity found in cells: mean±S.E.M. of three independ-
ent experiments in duplicate. PL, phospholipids; DG, digly-
cerides; TG, triglycerides; AA, arachidonic acid.and PL. Less than 10% of label is recovered in DG or
as free AA, and labeled MG are not detected. A transfer
of AA  from TG  to PL has  been  reported in  several
human  cell  types.11 This trafficking  is not found  in
U266, IM9 and OPM2 cells. Authors have suggested
that the  incorporation of  [3H]AA into  the different
cellular  lipid  species  does  not  exactly  reflect  the
distribution of the arachidonate mass in them, since
the exogenous [3H]AA might be incorporated into the
less  abundant AA-containing lipid  species.12 In  our
experimental conditions the addition of unlabeled AA
(0.1m M) into culture medium has no significant effect
on the incorporation and distribution of [3H]AA in PL
and  TG  of  U266,  IM9  and  OPM2  cells  (data  not
shown). Finally the base hydrolysis of labeled PL from
myeloma  cells  results  in  the  loss  of  98%  (mean  of
three experiments) of radioactivity, which was recov-
ered as free fatty acid. Similarly, treatment of labeled
PL with PLA2 from bovine pancreas leads to the loss
of 90% (mean of three experiments) of label. Thus,
base hydrolysis and PLA2-treatment experiments indi-
cate  that  [3H]AA  is  incorporated  unmodified  in
myeloma cell PL and is linked by an ester bond.
The distribution of  [3H]AA into PL species using
myeloma cells labeled for 30min is reported in Table
1. PC and PE are the major PL species in OPM2, IM9
and U266 cells. Prelabeling-chase experiments have
documented a trafficking of labeled AA from PC to PE
in several inflammatory cell types.13To investigate the
putative exchange of labeled AA between PL species,
myeloma cells labeled for 30min were washed and
grown  in  culture  medium  free  of  [3H]AA  for  7h.
Under these experimental conditions no trafficking of
[3H]AA from PC to PE is documented for OPM2, U266
and IM9 cells (data not shown). Studies report that
lipoxygenase  and  cyclooxygenase  products  of  AA
might  derive  from  different  PL  species  in  some
inflammatory cell types.12Thus, two sources of AA are
released  during  immunological  activation  of  mast
cells.14 PC provides AA for LTs biosynthesis, while PE
provides the released AA that might be used for the
production of cyclooxygenase products. Clearly the
role of the different PL species on the production of
lipoxygenase and cyclooxygenase metabolites of AA
by human myeloma cells deserve to be investigated.
The addition of lipoxygenase metabolite of AA is
reported  to  modulate  the  growth  of  various  cell
types.5–7 We then assessed their putative role on the
proliferation of human myeloma cells. As reported in
Table 2, the addition of micromolar amounts of AA,
LTB4, LTC4, LXA4, LXB4, 12-HETE and 15-HETE has no
significant (P>0.05, Mann–Whitney U-test, four inde-
pendent  experiments)  effect  on  the  [3H]thymidine
incorporation  of  U266,  IM9  and  OPM2  cells. This
result  is in  accord with the fact that the enhanced
B-cell proliferation caused by lipoxygenase blockade
could not be reversed by the exogenous addition of
LTs or HETEs.2 In this study we have only investigated
the  effects  of  lipoxygenase  products  of AA  on  the
growth of myeloma cells. However, cyclooxygenase
products of AA such as prostaglandin E2 are reported
to modulate the proliferation of several cell types.15,16
Clearly their role on the growth of U266,  IM9  and
OPM2 cells deserves to be clarified.
In conclusion, while human myeloma cells incorpo-
rate AA  in  their  membrane  phospholipids  and  tri-
glycerides, exogenous AA and lipoxygenase products
are not important modulators of their proliferation, a
result that markedly differs to their reported endoge-
nous role.
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